1.Sales and profit
See section β- Ascentage Pharma Group International had $79.9M of revenue in fiscal 2025, down 41.4% on the year before.
- Ascentage Pharma Group International lost $173M in fiscal 2025.
Ascentage Pharma Group International
AAPG Nasdaq Pharmaceutical Preparations Financials FY2022βFY2025
Ascentage Pharma Group International had $79.9M of revenue in fiscal 2025, down 41.4% on the year before.
Download report
3-page PDF: the company, its results and charts with peers.
Last close Β· Oct 23, 2026
$15.44
3.5%KIRAβs summary AI analyst
Hi! I read Ascentage Pharma Group Internationalβs latest annual report (fiscal 2025). Here is what stands out:
3 to watch
2.Cash and shareholders
See section β- Free cash flow was β$167M in fiscal 2025, β209.3% of revenue.
- Ascentage Pharma Group International returned $1.3M to shareholders in fiscal 2025. The diluted share count rose 17.9%.
- No open-market insider trades in the last 12 months.
3.Financial health
See section β- Ascentage Pharma Group International owes $112M more than it holds in cash.
Ascentage Pharma Group International in 30 seconds
Good So-so Weak
Weak
Are sales growing?
β41.4%
No. Sales fell 41.4% last year.
Weak
Does it make a profit?
β216.5%
No. It lost money last year.
Weak
Does profit turn into cash?
β209.3%
No. It spent more cash than it brought in.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$1.4B
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$1.94 EPS (TTM)
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Ascentage Pharma Group International did it, and the next one. Share prices often move a lot on those days.
Next results
April 28, 2027
Wednesday Β· in 185 days
- Time
- After the market closes
- Covers
- Period ended Dec 31, 2026
- Source
- Stoqly estimate
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week βRevenue and margins
KIRA Β· Ascentage Pharma Group International had $79.9M of revenue in fiscal 2025, down 41.4% on the year before.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY22
Revenue $31.1M
FY23
Revenue $31.3M
FY24
Revenue $136M
FY25
Revenue $79.9M
Margins, % of revenue
FY22
Gross 89.5%
Operating β
Net β421.0%
FCF β408.8%
FY23
Gross 86.2%
Operating β
Net β417.0%
FCF β347.9%
FY24
Gross 97.0%
Operating β
Net β41.3%
FCF β13.8%
FY25
Gross 91.5%
Operating β
Net β216.5%
FCF β209.3%
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Ascentage Pharma Group International lost $173M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY22
Net income β$131M
FY23
Net income β$131M
FY24
Net income β$56.3M
FY25
Net income β$173M
Diluted EPS
FY22
Diluted EPS β$1.99
FY23
Diluted EPS β$1.85
FY24
Diluted EPS β$0.74
FY25
Diluted EPS β$1.94
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$167M in fiscal 2025, β209.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY22
Free cash flow β$127M
FY23
Free cash flow β$109M
FY24
Free cash flow β$18.8M
FY25
Free cash flow β$167M
Cash from operations vs capital spending
FY22
Cash from operations β$97.1M
Capital spending $30.2M
FY23
Cash from operations β$103M
Capital spending $6.5M
FY24
Cash from operations β$15.5M
Capital spending $3.4M
FY25
Cash from operations β$163M
Capital spending $3.8M
Cash from operations
Capital spending
Dividends, buybacks and share count
KIRA Β· Ascentage Pharma Group International returned $1.3M to shareholders in fiscal 2025. The diluted share count rose 17.9%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY22
Dividends β
Buybacks $4.0M
FY23
Dividends β
Buybacks $0.8M
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks $1.3M
Dividends
Buybacks
Diluted shares outstanding (annual)
FY22
Diluted shares 0.07B
FY23
Diluted shares 0.07B
FY24
Diluted shares 0.08B
FY25
Diluted shares 0.09B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
KIRA Β· Ascentage Pharma Group International owes $112M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Ascentage Pharma Group International can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY22
Cash $195M
Debt β
FY23
Cash $146M
Debt $253M
FY24
Cash $122M
Debt $229M
FY25
Cash $171M
Debt $283M
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $195M | $146M | $122M | $171M |
| Debt incl. finance leases | β | $253M | $229M | $283M |
| Debt / equity | β | 29.7x | 6.3x | 1.5x |
| Current ratio | β | 1.4x | 1.3x | 1.8x |
| Quick ratio | β | 1.4x | 1.3x | 1.8x |
| Total liabilities | β | $342M | $321M | $376M |
| Shareholders' equity | $59.2M | $8.5M | $36.2M | $189M |
| Net debt (β = net cash) | β | $107M | $106M | $112M |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY22
Return on capital β
Return on equity β221.4%
Return on assets β
FY23
Return on capital β
Return on equity β385.8%
Return on assets β
FY24
Return on capital β
Return on equity β252.1%
Return on assets β
FY25
Return on capital β
Return on equity β153.4%
Return on assets β
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | β | β | β | β |
| Cash from operations is positive | β | β | β | β |
| Return on assets rose | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β |
| Debt fell relative to assets | β | β | β | β |
| Current ratio rose | β | β | β | β |
| Share count didn't rise | β | β | β | β |
| Gross margin rose | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β |
| F-score | β / 3 | β / 5 | β / 6 | β / 6 |
| Accruals ratio | β | β | β | β |
| Altman Z'' | β | β | β | β |
All figures
Every number, year by year.
4 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $31.1M | $31.3M | $136M | $79.9M |
| Gross profit | $27.9M | $27.0M | $132M | $73.1M |
| Research and development | $110M | $99.8M | $132M | $158M |
| Interest expense | $7.8M | $13.6M | $9.0M | $7.5M |
| Pretax income | β$132M | β$132M | β$54.9M | β$172M |
| Income tax | β$0.6M | β$1.0M | $1.4M | $1.0M |
| Net income | β$131M | β$131M | β$56.3M | β$173M |
| Net income to common | β$131M | β$131M | β$56.3M | β$173M |
| Diluted EPS | β$1.99 | β$1.85 | β$0.74 | β$1.94 |
| Diluted shares | 0.07B | 0.07B | 0.08B | 0.09B |
| Cash flow | ||||
| Cash from operations | β$97.1M | β$103M | β$15.5M | β$163M |
| Capital expenditure | $30.2M | $6.5M | $3.4M | $3.8M |
| Free cash flow | β$127M | β$109M | β$18.8M | β$167M |
| Stock-based compensation | $3.3M | $4.4M | $2.9M | $2.9M |
| Share buybacks | $4.0M | $0.8M | β | $1.3M |
| Dividends and buybacks | $4.0M | $0.8M | β | $1.3M |
| Balance sheet | ||||
| Cash and short-term investments | $195M | $146M | $122M | $171M |
| Total debt | β | $253M | $229M | $283M |
| Current assets | β | $189M | $202M | $421M |
| Current liabilities | β | $131M | $160M | $235M |
| Inventory | β | $2.3M | $0.9M | $4.1M |
| Property and equipment, net | β | $127M | $116M | $112M |
| Goodwill | β | $3.5M | $3.4M | $3.5M |
| Total liabilities | β | $342M | $321M | $376M |
| Shareholders' equity | $59.2M | $8.5M | $36.2M | $189M |
| Margins | ||||
| Gross margin | 89.5% | 86.2% | 97.0% | 91.5% |
| Net margin | β421.0% | β417.0% | β41.3% | β216.5% |
| FCF margin | β408.8% | β347.9% | β13.8% | β209.3% |
| Returns | ||||
| Return on equity | β221.4% | β385.8% | β252.1% | β153.4% |
| Return on tangible equity | β221.4% | β2,599.1% | β171.7% | β93.1% |
| Growth | ||||
| Revenue growth | β | 0.6% | 334.8% | β41.4% |
| Share count change | β | 7.1% | 7.0% | 17.9% |
| Financial health | ||||
| Debt / equity | β | 29.7x | 6.3x | 1.5x |
| Current ratio | β | 1.4x | 1.3x | 1.8x |
| Quick ratio | β | 1.4x | 1.3x | 1.8x |
| Capital allocation | ||||
| Capex / revenue | 96.9% | 20.8% | 2.5% | 4.8% |
| Stock comp / revenue | 10.5% | 14.2% | 2.1% | 3.6% |
Source: SEC EDGAR XBRL filings (CIK 0002023311). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CNY under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. Per-share figures are per US-listed share (1 ADS = 4 ordinary shares). For information only β not investment advice. Check the original filings before relying on any figure.